Search results
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Benzinga via Yahoo Finance· 4 days agoWednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in...
Manage Your Asthma: FDA on Know Your Triggers and Treatment Options
Sierra Sun Times· 6 days agoAsthma is a chronic lung disease that causes the airways to become inflamed and narrow. Symptoms of...
Asthma Triggers In Homes Can Send Kids to the ER—This Organization Is Working to Change That
Health.com· 6 days agoFor parents of children with asthma, witnessing an attack of severe symptoms can be a terrifying...
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient...
Benzinga via Yahoo Finance· 6 days agoThe primary results showed that treatment with Tezspire led to a 17% numerical reduction in the...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 4 days agoGSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma...
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Benzinga via Yahoo Finance· 5 days agoTuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and...
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
Morningstar· 6 days agoGSK's experimental drug for asthma met its goals in the latest trial, moving a treatment with potential annual peak sales of more than 3 billion pounds ...
GSK's experimental drug shows promise in reducing severe asthma attacks
AOL· 6 days agoThe drug, called depemokimab, showed "significant and meaningful reductions" in asthma attacks for patients with eosinophilic asthma, GSK said on Tuesday ...
Sanofi reports positive data from Phase II asthma treatment trial
Clinical Trials Arena via Yahoo Finance· 4 days agotreatment-emergent adverse event (TEAE), with a higher incidence in the rilzabrutinib group versus...
GSK finds success in severe asthma drug trials
Becker’s Hospital Review· 6 days agoThe drug candidate, depemokimab, was measured in severe asthma patients with Type 2 inflammation characterized by blood eosinophil count, GSK said in a ...